Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049751 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL19420453 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL3867845 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL783223 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5271544 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4168243 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL562559 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL29833737 | 0.83 | ANPEP (0.42) | KDM1AANPEPGRIN2DGRIN3BGRIN1 | |
| SCHEMBL8309860 | 0.79 | KDM1A (0.47) | KDM1AANPEPHTR2ASIGMAR1GRIN2D | |
| SCHEMBL1240196 | 0.79 | KDM1A (0.47) | KDM1AANPEPHTR2ASIGMAR1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004013083-A1 | NOLOMIROLE HYDROCHLORIDE FORM I | CHIESI FARMACEUTICI S. P. A. (IT) | 2004-02-12 | — | — | WO | disclosed |
| EP-1384708-A1 | Process for the manufacture of form I of nolomirole hydrochloride | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-01-28 | — | — | EP | disclosed |
| EP-1200079-A2 | 2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA | CHIESI FARMACEUTICI S.p.A. (IT) | 2002-05-02 | — | — | EP | disclosed |
| US-6331636-B1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, DIABETES, HYPERTENSION, IMPOTENCY, APPETITE CONTROL | THE UPJOHN COMPANY | 2001-12-18 | — | — | US | disclosed |
| WO-2001008667-A2 | 2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA | CHIESI FARMACEUTICI S.P.A. (IT) | 2001-02-08 | — | — | WO | disclosed |
| EP-0476016-B1 | CNS active 8-heterocyclyl-2-aminotetralin derivatives | UPJOHN CO (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0788472-A1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMACEUTICI S.p.A. (IT) | 1997-08-13 | — | — | EP | disclosed |
| US-5545755-A | USEFUL TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS, HYPERTENSION, DIABETES, SEXUAL IMPOTENCY AND TO CONTROL APPETITE | THE UPJOHN COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1995029147-A1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 1995-11-02 | — | — | WO | disclosed |
| EP-0476016-A1 | THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| WO-1990015047-A1 | THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4346112-A | Composition and method for treating patients having Parkinson's Disease | UNIVERSITY PATENTS INC. (US) | 1982-08-24 | — | — | US | disclosed |